OTCMKTS:SPHS Sophiris Bio (SPHS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Sophiris Bio Stock (OTCMKTS:SPHS) Get Sophiris Bio alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket Capitalization$4 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Sophiris Bio is a clinical-stage biopharmaceutical company focused on developing targeted therapies for urological and related conditions. Headquartered in King of Prussia, Pennsylvania, the company leverages proprietary protein engineering to create treatments designed for localized delivery, aiming to minimize systemic side effects and improve patient outcomes. The company’s lead therapeutic candidate, PRX302 (also known as topsalysin), is an injectable proaerolysin-based therapy designed to selectively destroy prostate tissue in patients with benign prostatic hyperplasia (BPH) and localized prostate cancer. PRX302 has advanced through multiple Phase 2 clinical trials, demonstrating the potential to provide durable symptom relief with a favorable safety profile. In addition, Sophiris Bio is developing PRX124, an intradetrusor injectable therapy intended to address female stress urinary incontinence by selectively targeting and remodeling the urethral sphincter region. Sophiris Bio’s development programs are supported by ongoing interactions with regulatory authorities in the United States, and the company is preparing for pivotal studies to potentially bring its urology-focused candidates closer to commercialization. By concentrating on high-need areas within men’s and women’s health, Sophiris Bio seeks to establish strategic partnerships and licensing arrangements that can accelerate late-stage development and expand global access to its innovative treatment portfolio.AI Generated. May Contain Errors. Read More Receive SPHS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sophiris Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPHS Stock News HeadlinesBest Louisiana High SchoolsOctober 13, 2023 | usnews.comBLTE - Belite Bio, IncJuly 20, 2023 | finance.yahoo.comRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.October 8 at 2:00 AM | Stansberry Research (Ad)Bio-Reference LaboratoriesJune 12, 2023 | forbes.comSophiris Bio Inc. Registered Sh (BFF1.SG)March 20, 2023 | finance.yahoo.comSPHS Indoor Track Wins Girls Blue Division at GMC ChampionshipsJanuary 25, 2023 | msn.comSPHS Weekly Sports Recap: All Sports Notch Big WinsJanuary 17, 2023 | msn.comSee More Headlines SPHS Stock Analysis - Frequently Asked Questions How were Sophiris Bio's earnings last quarter? Sophiris Bio, Inc. (OTCMKTS:SPHS) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.02. How do I buy shares of Sophiris Bio? Shares of SPHS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sophiris Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sophiris Bio investors own include Sarepta Therapeutics (SRPT), Intercept Pharmaceuticals (ICPT), (CPXX) (CPXX), SELLAS Life Sciences Group (SLS), Advanced Micro Devices (AMD), Rigel Pharmaceuticals (RIGL) and Anavex Life Sciences (AVXL). Company Calendar Last Earnings5/09/2019Today10/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:SPHS CIK1563855 Webwww.sophirisbio.com Phone(858) 777-1760FaxN/AEmployees6Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares35,550,000Free FloatN/AMarket Cap$4 thousand OptionableNot Optionable Beta1.94 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (OTCMKTS:SPHS) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn Early Move On The Next Shift In CoinLitecoin is already processing 500,000+ daily transactions, integrated with PayPal and Revolut, and now one fi...Market Tactic | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sophiris Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sophiris Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.